Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Prostate Cancer
Interventions: MR-Guided Transurethral US Ablation of Prostate Tissue; Device
Lead sponsor: Profound Medical Inc.; Other
Eligibility: 65 Years to 75 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Cardiovascular Diseases, Metabolic Syndrome
Interventions: Dried Fruit, High Carbohydrate Snack; Dietary Supplement · Other
Lead sponsor: Penn State University; Other
Eligibility: 25 Years to 60 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Lung Cancer
Interventions: Cs-131 brachytherapy seeds; Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Opioid Consumption, Postoperative
Interventions: Suzetrigine, Standard Care (in control arm); Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Leiomyosarcoma, Uterine Neoplasm
Interventions: gemcitabine, docetaxel, doxorubicin; Drug
Lead sponsor: Sarcoma Alliance for Research through Collaboration; Other
Eligibility: 18 Years and older · Female only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 12
States / cities: Washington D.C., District of Columbia • Tampa, Florida • Atlanta, Georgia + 8 more

Conditions: Sternal Wound Infection, Mediastinitis
Interventions: Rapid Sternal Closure System, Conventional wire closure; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cervix Carcinoma
Interventions: Proflavine, High-Resolution Microendoscopy (HRME) Imaging; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 21 Years to 64 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions: Nivolumab, Cisplatin, Cetuximab, IMRT; Drug · Radiation
Lead sponsor: RTOG Foundation, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 11
States / cities: Palo Alto, California • Orlando, Florida • Atlanta, Georgia + 8 more

Conditions: High-Grade Anal Intraepithelial Neoplasia
Interventions: Lopinavir / Ritonavir; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pre-diabetes, Metabolic Syndrome
Interventions: Active, Control; Dietary Supplement
Lead sponsor: Clinical Nutrition Research Center, Illinois Institute of Technology; Industry
Eligibility: 25 Years to 60 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV, AIDS
Interventions: Kaletra (drug); Drug
Lead sponsor: Lampiris, Harry W., M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: San Francisco, California

Conditions: GVHD, Hematologic Neoplasms
Interventions: Cyclophosphamide, abatacept, Methotrexate, Tacrolimus; Drug
Lead sponsor: Dimitrios Tzachanis, MD PhD; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Hypertension
Interventions: High Intensity Intervention, Low Intensity Intervention, All- 6 month pharmacist intervention; Other
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: fluphenazine hydrochloride; Drug
Lead sponsor: Immune Control; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 3
States / cities: Hackensack, New Jersey • New Hyde Park, New York • Philadelphia, Pennsylvania

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Unresectable Breast Carcinoma, Metastatic Melanoma, Unresectable Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Soft Tissue Sarcoma, Bone Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone, Basal Cell Carcinoma
Interventions: Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Poly ICLC, Radiation Therapy, Recombinant Flt3 Ligand, Pembrolizumab, Tocilizumab; Biological · Drug · Radiation
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions: PAC-1 Compound; Drug
Lead sponsor: Vanquish Oncology, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Chicago, Illinois • Baltimore, Maryland • Saint Paul, Minnesota

Conditions: Suicide Prevention
Interventions: Virtual Crisis Response Planning, In-Person Crisis Response Planning, Crisis Risk Counseling; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 14 Years to 18 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Parkinson Disease
Interventions: Resistance Exercise via Negative Eccentric Work, Standard care exercise training; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 40 Years to 90 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Soft Tissue Sarcoma
Interventions: Ascorbate; Drug
Lead sponsor: Mohammed Milhem; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Epilepsy
Interventions: Brain Interchange System; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 3 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Rochester, Minnesota • Houston, Texas

Conditions: Neonatal Abstinence Syndrome, Opioid-use Disorder
Interventions: Mobile-based NAS Caregiving Tool; Behavioral
Lead sponsor: Washington State University; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Ischemic Heart Disease
Interventions: Not listed
Lead sponsor: Piedmont Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism, Trauma
Interventions: The Angel® Catheter; Device
Lead sponsor: BiO2 Medical; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 21
States / cities: Los Angeles, California • San Diego, California • Loveland, Colorado + 18 more

Conditions: Radiation Retinopathy
Interventions: ranibizumab 2.0 mg; Drug
Lead sponsor: The New York Eye Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer

Effect of Dried Fruit on Cardiometabolic Risk Factors

Cesium-131 Seed Brachytherapy Plus Subtotal Resection for Lung Cancer Patients

Precision Pain Management - A Randomized Clinical Trial Assessing the Efficacy of Suzetrigine on Postoperative Analgesia Among Surgical Patients at Higher Risk for Persistent Postoperative Opioid Use (POU)

Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma

Rapid Sternal Closure System (TALON)

Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix

Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer

Lopinavir/Ritonavir in PLWH With High-Grade AIN

Replacing Refined Carbohydrates With Healthy Fats on Cardio-metabolic Markers

High Dose Ritonavir/Lopinavir Liquid Formulation in Salvage Therapy for Protease Inhibitor Resistant HIV Disease

Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation

Trial of Low and High Intensity Strategies to Maintain BP Control

Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2

Feasibility Trial of a Single Session of Crisis Response Planning for Youth at High Risk for Suicide

Strength Training and Medication Effects in Parkinson Disease Effects on Hypokinesia in Parkinson Disease

High Dose Ascorbate With Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas

Acute Stimulation and Modulation of Stereotyped High-Frequency Oscillations

Effective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk Pregnant Women

In-hospital and Long-term Outcomes for Percutaneous Chronic Total Coronary Occlusion Revascularization in a High-volume, Multi-operator Program

The Angel® Catheter Pivotal Clinical Trial

High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy